Trial Outcomes & Findings for Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors (NCT NCT04493333)
NCT ID: NCT04493333
Last Updated: 2024-11-27
Results Overview
The change in the subject's calculated VMI from baseline to the end of treatment at 12 weeks (±1 week). VMI = 1.0 x %S + 0.5 x %I + 0.0 x %P cells, which is the same as VMI = %S + (0.5 x %I) when simplified. It has a potential range of 0-100. A VMI of 65-100 suggests a normal premenopausal environment, 50-64 indicates a moderate estrogenic effect, and \< 50 indicates atrophy.
TERMINATED
PHASE2
8 participants
Baseline and 12 weeks (±1 week)
2024-11-27
Participant Flow
Potential subjects will be identified in the UAMS CI and UAMS Women's Health clinics and from the CARTI Cancer Center, during routine clinic appointments by the provider or research staff. Potential research subjects may also contact the UAMS Cancer Institute's Clinical Trials Office regarding participation based on the information found within the IRB-approved DHEA flyer that is to be distributed amongst UAMS and the CARTI medical clinics.
Females of childbearing age and potential must have negative pregnancy test at screening. Any consented individuals who do not indicate sexual complaints on Question 1 of the BSSC-W at baseline will be considered a screen fail and will not complete the FSFI or continue in the study.
Participant milestones
| Measure |
Intrarosa & Standard of Care Aromatase Inhibitor
Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).
|
Replens & Standard of Care Aromatase Inhibitor
Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).
|
|---|---|---|
|
Overall Study
STARTED
|
5
|
3
|
|
Overall Study
COMPLETED
|
2
|
0
|
|
Overall Study
NOT COMPLETED
|
3
|
3
|
Reasons for withdrawal
| Measure |
Intrarosa & Standard of Care Aromatase Inhibitor
Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).
|
Replens & Standard of Care Aromatase Inhibitor
Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
1
|
1
|
|
Overall Study
Ineligible
|
0
|
1
|
|
Overall Study
Noncompliance
|
2
|
1
|
Baseline Characteristics
Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
Baseline characteristics by cohort
| Measure |
Intrarosa & Standard of Care Aromatase Inhibitor
n=5 Participants
Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).
|
Replens & Standard of Care Aromatase Inhibitor
n=3 Participants
Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).
|
Total
n=8 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
57.8 years
STANDARD_DEVIATION 3.96 • n=99 Participants
|
54.00 years
STANDARD_DEVIATION 15.39 • n=107 Participants
|
56.38 years
STANDARD_DEVIATION 8.98 • n=206 Participants
|
|
Sex: Female, Male
Female
|
5 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=99 Participants
|
1 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Race (NIH/OMB)
White
|
4 Participants
n=99 Participants
|
2 Participants
n=107 Participants
|
6 Participants
n=206 Participants
|
|
Race (NIH/OMB)
More than one race
|
1 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
1 Participants
n=206 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=99 Participants
|
0 Participants
n=107 Participants
|
0 Participants
n=206 Participants
|
|
Region of Enrollment
United States
|
5 Participants
n=99 Participants
|
3 Participants
n=107 Participants
|
8 Participants
n=206 Participants
|
|
Vaginal Maturation Index (VMI)
|
50.83 Units on a scale
STANDARD_DEVIATION 16.65 • n=99 Participants
|
36.67 Units on a scale
STANDARD_DEVIATION 23.23 • n=107 Participants
|
43.75 Units on a scale
STANDARD_DEVIATION 19.67 • n=206 Participants
|
PRIMARY outcome
Timeframe: Baseline and 12 weeks (±1 week)Population: Out of 8 participants assigned to a treatment arm, only 2 had VMI measured at both the baseline and 12-week visits.
The change in the subject's calculated VMI from baseline to the end of treatment at 12 weeks (±1 week). VMI = 1.0 x %S + 0.5 x %I + 0.0 x %P cells, which is the same as VMI = %S + (0.5 x %I) when simplified. It has a potential range of 0-100. A VMI of 65-100 suggests a normal premenopausal environment, 50-64 indicates a moderate estrogenic effect, and \< 50 indicates atrophy.
Outcome measures
| Measure |
Intrarosa & Standard of Care Aromatase Inhibitor
n=2 Participants
Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).
|
Replens & Standard of Care Aromatase Inhibitor
Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).
|
|---|---|---|
|
Difference in Vaginal Maturation Index (VMI) Response From Baseline to Week 12
|
-7.5 Units on a scale
Standard Deviation 24.75
|
—
|
SECONDARY outcome
Timeframe: 12 weeks (±1 week)Population: Out of 8 participants assigned to a treatment arm, only 2 had vaginal pH measured at both the baseline and 12-week visits.
Vaginal pH was used as an objective physiologic marker to determine the improvement in vaginal atrophy. pH is a measure of acidity and alkalinity and can range from 0 to 14, with 7 being neutral. Lower pH scores are acidic and higher pH scores are basic or alkaline. A normal healthy vaginal pH is 4.5. As the vaginal epithelium becomes thinner and more atrophic, the mucosa has less glycogen content and less lactobacilli to convert the glycogen into lactic acid, which results in an increase in the vaginal pH.
Outcome measures
| Measure |
Intrarosa & Standard of Care Aromatase Inhibitor
n=2 Participants
Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).
|
Replens & Standard of Care Aromatase Inhibitor
Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).
|
|---|---|---|
|
Difference in Vaginal pH From Baseline to Week 12
|
-1.00 Units on a scale
Standard Deviation 2.83
|
—
|
SECONDARY outcome
Timeframe: 12 weeks (±1 week)Population: Out of 8 participants assigned to a treatment arm, only 2 took the BSSC-W at both the baseline and 12-week visits.
The Dyspareunia Score on the BSSC-W asks if there is a problem with pain during sex. A difference score of 0 indicated no change in whether it was a problem. The min and max are both 0 which makes the range also 0. Only 2 participants had week 12 scores. These scores were both 1. (So the min and max were 1 with the range being 0.) Of the baseline scores, these 2 participants both had scores of 1 again. (So the min and max for these 2 participants were both 1 with a range of 0.) If we include these 2 participants with the other 6 who have baseline dyspareunia scores on the BSSC-W, then 7 participants has a score of 1 and 1 participant had a score of 0. This would make the min, max, and range 0, 1, and 1 respectively. As for which value represents a better or worse outcome, 1 indicates presence of dyspareunia while 0 indicates absence of dyspareunia, so 1 is a worse outcome than 0. Subscales are not combined here to produce a total score.
Outcome measures
| Measure |
Intrarosa & Standard of Care Aromatase Inhibitor
n=2 Participants
Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).
|
Replens & Standard of Care Aromatase Inhibitor
Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).
|
|---|---|---|
|
Difference in Dyspareunia Scores on the Brief Sexual Symptom Checklist for Women (BSSC-W) From Baseline to Week 12
|
0.00 Units on a scale
Standard Deviation 0.00
|
—
|
SECONDARY outcome
Timeframe: 12 weeks (±1 week)Population: Out of 8 participants assigned to a treatment arm, only 2 took the BSSC-W at both the baseline and 12-week visits.
The min and the max are both 0 which make the range also 0. These were obtained from subtracting each participant's score at baseline from their score at week 12. Only 2 participants had week 12 scores. These scores were both 1. Of the baseline scores, these 2 participants both had scores of 1 again. If 2 participants with the other 6 have baseline dyspareunia scores on the BSSC-W, then 7 participants have a score of 1 and 1 participant had a score of 0. This would make the min, max, and range 0, 1, and 1 respectively. As for which value represents a better or worse outcome, 1 indicates presence of vaginal dryness (problem with decreased vaginal lubrication) while 0 indicates absence of vaginal dryness (or an absence of this problem of decreased vaginal lubrication), so 1 is a worse outcome than 0. Subscales are not combined here to produce a total score.
Outcome measures
| Measure |
Intrarosa & Standard of Care Aromatase Inhibitor
n=2 Participants
Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).
|
Replens & Standard of Care Aromatase Inhibitor
Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).
|
|---|---|---|
|
Difference in Vaginal Dryness Scores on the Brief Sexual Symptom Checklist for Women (BSSC-W) From Baseline to Week 12
|
0.00 Units on a scale
Standard Deviation 0.00
|
—
|
SECONDARY outcome
Timeframe: 12 weeks (±1 week)Population: Out of 8 participants assigned to a treatment arm, only 2 took the FSFI at both the baseline and 12-week visits.
The Dyspareunia Subscale Score on the Female Sexual Dysfunction Index ranges from 0-5 with higher scores indicating better sexual function, so less dyspareunia.
Outcome measures
| Measure |
Intrarosa & Standard of Care Aromatase Inhibitor
n=2 Participants
Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).
|
Replens & Standard of Care Aromatase Inhibitor
Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).
|
|---|---|---|
|
Difference in Dyspareunia Subscale Scores on the Female Sexual Dysfunction Index (FSFI) From Baseline to Week 12
|
2.20 Units on a scale
Standard Deviation 3.11
|
—
|
SECONDARY outcome
Timeframe: 12 weeks (±1 week)Population: Out of 8 participants assigned to a treatment arm, only 2 took the FSFI at both the baseline and 12-week visits.
The Vaginal Dryness (or Lubrication) Subscale Score on the Female Sexual Dysfunction Index ranges from 0-5 with higher scores indicating better sexual function, so more lubrication.
Outcome measures
| Measure |
Intrarosa & Standard of Care Aromatase Inhibitor
n=2 Participants
Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).
|
Replens & Standard of Care Aromatase Inhibitor
Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).
|
|---|---|---|
|
Difference in Vaginal Dryness Subscale Scores on the Female Sexual Dysfunction Index (FSFI) From Baseline to Week 12
|
1.80 Units on a scale
Standard Deviation 2.55
|
—
|
SECONDARY outcome
Timeframe: 12 weeks (±1 week)Population: Out of 8 participants assigned to a treatment arm, only 2 took the QOL-CSV at both the baseline and 12-week visits.
The Quality of Life - Cancer Survivor Version ranges from 0-10 with higher scores indicating a higher quality of life. T here are only 2 difference scores for each of the 4 subscales. The min, max, and ranges of these Well-Being Subscales: Physical -1.00, -0.62, and 0.38. Psychological -0.72, 0.94, and 1.67. Social 0.75, 1.25, and 0.50. Spiritual -1.57, 3.29, and 4.86. For Psychological the min, max, and range are 2.61, 6.83, and 4.22. For Social the min, max, and range are 2.63, 7.38, and 4.75. For Spiritual the min, max, and range are 4.43, 8.43, and 4.00. A negative difference score indicates a worsening of quality of life while a positive score indicates that qualify of life got better. Subscales were not combined here to produce a total score. For the baseline and week 12 scores on the QOL-CSV, higher scores mean higher quality of life.
Outcome measures
| Measure |
Intrarosa & Standard of Care Aromatase Inhibitor
n=2 Participants
Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).
|
Replens & Standard of Care Aromatase Inhibitor
Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).
|
|---|---|---|
|
Difference in Quality of Life on the Quality of Life - Cancer Survivor Version (QOL-CSV) From Baseline to Week 12
QOL-CSV Physical Well-Being Subscale
|
-0.81 Units on a scale
Standard Deviation 0.27
|
—
|
|
Difference in Quality of Life on the Quality of Life - Cancer Survivor Version (QOL-CSV) From Baseline to Week 12
QOL-CSV Psychological Well-Being Subscale
|
0.11 Units on a scale
Standard Deviation 1.18
|
—
|
|
Difference in Quality of Life on the Quality of Life - Cancer Survivor Version (QOL-CSV) From Baseline to Week 12
QOL-CSV Social Well-Being Subscale
|
1.00 Units on a scale
Standard Deviation 0.35
|
—
|
|
Difference in Quality of Life on the Quality of Life - Cancer Survivor Version (QOL-CSV) From Baseline to Week 12
QOL-CSV Spiritual Well-Being Subscale
|
0.86 Units on a scale
Standard Deviation 3.43
|
—
|
Adverse Events
Intrarosa & Standard of Care Aromatase Inhibitor
Replens & Standard of Care Aromatase Inhibitor
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Intrarosa & Standard of Care Aromatase Inhibitor
n=5 participants at risk
Subjects randomized to the Intrarosa® arm will use 6.5 mg daily for 12 weeks (±1 week).
|
Replens & Standard of Care Aromatase Inhibitor
n=3 participants at risk
Subjects randomized to the Replens™ arm will use a vaginal applicator two times per week for 12 weeks (±1 week).
|
|---|---|---|
|
Gastrointestinal disorders
Bloating
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
General disorders
Burning with vaginal Intrarosa application
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Reproductive system and breast disorders
Dyspareunia
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
General disorders
Fatigue
|
40.0%
2/5 • Number of events 2 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Nervous system disorders
Headache
|
40.0%
2/5 • Number of events 2 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Infections and infestations
Herpes simplex reactivation
|
20.0%
1/5 • Number of events 3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Skin and subcutaneous tissue disorders
Hirsutism
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
0.00%
0/5 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
33.3%
1/3 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Psychiatric disorders
Insomnia
|
40.0%
2/5 • Number of events 2 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Psychiatric disorders
Irritability
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Gastrointestinal disorders
Nausea
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Reproductive system and breast disorders
Other, specify: Vaginal pulsing sensation
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Reproductive system and breast disorders
Other, specify: Vulva swelling
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Reproductive system and breast disorders
Other: Vaginal fullness
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Reproductive system and breast disorders
Pelvic pain
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/5 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
33.3%
1/3 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Vascular disorders
Thromboembolic event
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Infections and infestations
Upper respiratory infection
|
0.00%
0/5 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
33.3%
1/3 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Renal and urinary disorders
Urinary retention
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Reproductive system and breast disorders
Vaginal discharge
|
60.0%
3/5 • Number of events 3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Reproductive system and breast disorders
Vaginal dryness
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Infections and infestations
Vaginal infection
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Reproductive system and breast disorders
Vaginal pain
|
40.0%
2/5 • Number of events 2 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
|
Metabolism and nutrition disorders
Vitamin D deficiency
|
20.0%
1/5 • Number of events 1 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
0.00%
0/3 • 12 weeks (+/- 1 week)
AEs are to be reported in a routine fashion at scheduled times during the trial. Certain AEs must be reported in an expedited fashion to allow for timely monitoring of subject safety and care.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place